

















daily	for	more	than	six	weeks.1 The condition affects approximately 
between 0.5 and 1% of the total population with a predominance in 
females	and,	in	general,	all	age	groups	as	well	as	all	socioeconomic	
classes of the population can be affected.2,3	An	 incidence	peak	has	




eral practitioners.5 It has been reported 0.27 - 2.1% in family practice 
consultation,	1-	4%	in	dermatological	outpatient	department	and	>	
10%	were	identified	in	preselected	patients	in	allergy	or	dermatol-
ogy clinics.6,7 The duration of the disease in adults is variable and 
long	lasting:	6–12	weeks	in	52.8%,	3-6	months	in	18.5%,	7-12	months	
in	9.4%,	1-5	years	in	8.7%,	and	over	5	years	in	11.3%	of	the	patients.1,2
CU types include spontaneous chronic urticaria and induc-
ible urticaria. Spontaneous chronic urticaria shows lesions that are 
not	triggered	by	consistent	or	identifiable	environmental	factors	while	
induced	urticaria	is	due	to	physical	or	chemical	identifiable	factors.8,9
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Despite	the	frequency	of	the	disease,	scarce	information	ex-
ists	 regarding	CU	 and	 its	 frequency	 as	well	 as	 the	 burden	 of	 the	
disease,	and	its	consequences	in	Argentina.




supplied helps to understand how the disease behaves worldwide 
aiding the application of best common standards. 
METHODS
Setting





Argentina.	 Buenos	Aires	City	 is	 the	 capital	 city	 of	Argentina	 and	




(the last two covering a population of approximately 18.3 million 






or	 708.9)	members	 of	 the	 IHMCP	and	with	 at	 least	 12	months	 of	
follow up were included in the study. 













each patient. Drug prescriptions and the number of consultations 
with primary care or specialist during the 12 months previous to the 
inclusion in the study were evaluated.
Information about spontaneous or induced CU as well as its 
associated comorbidities as other autoimmune or allergic disorders 
was	registered.	Special	care	of	the	treatment	habits	was	taken.	
Statistical analysis





denominator	was	 the	number	 of	 total	 affiliates	 of	 IHMCP.	Preva-
lence ratio was calculated for the entire population and then dis-
criminated for adult and pediatric members (less than 18 years old 
at	 diagnosis).	 The	 prevalence	 ratio	 for	 spontaneous	 and	 induced	
chronic	urticaria	and	between	gender	was	also	analyzed	per	100,000	
populations with 95% CI. Baseline characteristics of the patients 
evaluated were reported as percentages for categorical data and 
mean	with	its	standard	deviation	(SD)	for	continuous	data.	
This study was approved by the Ethics Committee prior to 









Baseline	 characteristics	 are	 displayed	 in	 table	 1.	We	 stratified	 the	
affected	patients	 in	 those	with	 spontaneous	 and	 induced	CU.	An	
increase	in	the	frequency	of	spontaneous	CU	was	observed	in	pe-
diatric as well as in adult patients compared with induced urticaria 
(Table	2).	On	December	31,	2014,	the	prevalence	rate	observed	was	
0.29	%	(CI	95%	0.26-0.31%).	When	we	split	the	population	into	pe-
diatric	 (less	 than	 18	 years)	 and	 adult	 populations,	 the	prevalence	









dermatologists follow in 10% of cases and the main treatment used 
was	second	generation	antihistamines,	being	the	first	line	treatment	
recommended by current guidelines.9
DISCUSSION
Global	knowledge	of	CU	epidemiology	and	characteristics	
is	 an	unmet	need.	This	work	 shows	new	data	because	 is	 the	first	
study	 performed	 in	Argentina	 and	 in	 the	 region	 to	 evaluate	 the	
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Table 1: Demographics at baseline of the population included
Variable N (%)
Total population 158,926




















Other autoimmune disease 14	(3)









Mean age 45±1.3 40±1.7 0.02
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Table 3: Estimated prevalence of chronic urticaria in the 
members of the health maintenance organization stratified by 
gender, age and spontaneous or induced condition
Members N Cases Prevalence ratio 95%CI
Entire IHMCP prevalence ratio
158,926 463 0.29 0.26-0.31
Entire prevalence ratio in males
74,755 154 0.20 0.17-0.24
Entire prevalence ratio in females
84,171 309 0.36 0.32-0.41
Adult CU prevalence ratio
114,168 395 0.34 0.31-0.38
Adult CU prevalence ratio in males
54,864 123 0.24 0.18-0.26
Adult CU prevalence ratio in females
59,304 272 0.45 0.40-0.51
Pediatric CU prevalence ratio 
44,758 68 0.15 0.11-0.20
Pediatric CU prevalence ratio in males
19,891 31 0.15 0.10-0.22
Pediatric CU prevalence ratio in females
24,867 37 0.14 0.11-0.20
Members N Cases Prevalence ratio 95%CI
Adult cases of spontaneous CU
114,168 266 0.23 0.20-0.26
Pediatric cases of spontaneous CU
44,758 44 0.1 0.07-0.13
Adult cases of induced CU
114,168 129 0.11 0.1-0.13
Pediatric cases of induced CU
44,758 24 0.05 0.03-0.07
Therefore,	 epidemiologic	 studies	 provide	 information	 concerning	
the	burden	of	a	society’s	particular	disease,	which	may	contribute	
to improve public health planning. 
In	 this	study,	we	report	a	prevalence	ratio	of	0.29%	in	 the	
entire	population	evaluated.	Our	findings	are	in	line	with	previous	
studies. Hellgren et al. found a point prevalence of around 0.1% in 
the total population of Sweden.14 More recently Gaig et al. reported 
a prevalence of CU in Spain of 0.6% in a population-based study in 
adults	with	a	significantly	higher	frequency	of	the	disease	in	women	
than	in	men	(OR=3.82,	95%	CI	1.56-9.37)	and	with	an	average	age	of	
onset of 40 years in affected patients similar to our study.8	Zuberbier	
et al. found in a cross-sectional study performed in a general popu-
lation	by	a	questionnaire	survey	to	13,300	inhabitants	of	Berlin,	Ger-
many,	a	lifetime	prevalence	for	CU	of	1.8%	(95%	CI	1.4-2.3%),	and	
prevalence for the 12 months before assessment of 0.8% (95% CI 0.6-
CU= chronic urticaria
1.1%),	in	which	70.3%	of	cases	found	were	female.4 Possible expla-
nations for this data variability can be due to differences in methods 
employed,	geographic	zone,	genetics,	and	cultural	characteristics.	
Our results showed a higher prevalence of adult CU com-
pared with data from Hellgren et al.	(0.35%),	but	lower	when	com-
pared	 with	 Gaig	 and	 Zuberbier	 (0.6%	 and	 0.8%,	 respectively).4,8	
Scarce	 information	 is	available	 for	pediatric	population.	Bruske	et 
al. in a recent study described a cumulative prevalence of CU in 
the	pediatric	population	(less	than	10	years	old)	of	14.5%	for	males	
and 16.2% for females.3	Nevertheless,	we	 observed	 that	 pediatric	
prevalence of CU was 0.15% for all CU cases. Some methodological 




females than in males in the entire population and also in adult cas-
es	(Table	3).	The	previous	is	in	line	with	other	studies	that	showed	
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a female/male ratio of almost 2/1 for CU the difference being more 
important	mainly	 in	 the	adult	population,	compared	with	 the	pe-
diatric.3
Regarding	 related	 conditions,	 because	many	 autoimmune	
diseases	overlap,	it	was	suggested	that	CU	might	be	related	to	oth-
er	 autoimmune	 diseases.	 Thyroid	 disease	 is	 the	 most	 frequently	
investigated disease in CU.15 The mechanism of this association is 
currently	unknown.	We	observed	that	8%	of	patients	had	hypothy-
roidism.	Allergic	diseases	 (asthma,	 rhinitis	 or	dermatitis)	 are	 also	
described	as	 related	conditions.	Zuberbier	 et al. reported a higher 
frequency	of	allergic	diseases	compared	to	our	population	(53%	vs.	
23%	in	our	study).4
We also observed that allergists follow CU patients in 47% 
of	cases,	dermatologists	follow	in	10%	of	cases	and	more	than	a	half	
of included patients were followed by specialists probably due to 
the	specific	management	that	patients	should	have	in	order	to	con-
trol the disease.16
The main treatment used was second generation antihis-
tamines,	 being	 the	 first	 line	 treatment	 recommended	 by	 current	
guidelines. First generation antihistamines have demonstrated 
major	side	effects,	such	as	sedation	and	anticholinergic	effects	and	
should not be currently used in the treatment of urticaria.17 We did 
not	 observe	 significant	differences	 regarding	 the	 treatment	 of	CU	
(spontaneous	and	induced)	 in	 the	adult	and	pediatric	population,	
however,	almost	in	50%	of	the	included	patients,	the	information	of	
treatment received was not available. 
Undoubtedly,	 a	weakness	 of	 the	 study	 is	 its	 retrospective	
design.	Another	weakness	is	that	the	results	were	obtained	from	an	
HMO	and	therefore	contain	a	selection	bias.	Consequently,	caution	
should be exercised if data are to be extrapolated. 
CONCLUSION
In	 conclusion	 we	 observed	 that	 CU	 affects	 a	 significant	
number of patients in our population and despite the prevalence 
being	slightly	lower	compared	with	studies	from	other	regions,	the	
clinical presentation and demographic characteristics do not seem 




agement characteristics of CU has been previously reported. The 
data	shown	 in	 this	 study	are	good	baseline	 information,	 showing	
how	CU	is	presented	in	a	developing	country,	therefore	offering	the	
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